Literature DB >> 34657971

Low albumin levels are independently associated with neonatal acute kidney injury: a report from AWAKEN Study Group.

Arwa Nada1, David Askenazi2, Juan C Kupferman3, Maroun Mhanna4, John D Mahan5, Louis Boohaker2, Linzi Li2, Russell L Griffin6.   

Abstract

BACKGROUND: Data from adult and pediatric literature have shown an association between albumin levels and AKI. Whether hypoalbuminemia and neonatal AKI are associated has not been studied.
METHODS: We evaluated the association of albumin with early (during the first postnatal week) and late (after the first postnatal week) AKI for 531 neonates from the Assessment of Worldwide AKI Epidemiology in Neonates (AWAKEN) database and for 3 gestational age (GA) subgroups: < 29, 29 to < 36, and ≥ 36 weeks GA.
RESULTS: Low albumin levels were associated with increased odds of neonatal AKI; for every 0.1 g/dL decrease in albumin, the odds of late AKI increased by 12% on continuous analysis. After adjustment for potential confounders, neonates with albumin values in the lowest quartiles (< 2.2 g/dL) had an increased odds of early [Adjusted Odd Ratio (AdjOR) 2.5, 95% CI = 1.1-5.3, p < 0.03] and late AKI [AdjOR 13.4, 95% CI = 3.6-49.9, p < 0.0001] compared to those with albumin in the highest quartile (> 3.1 g/dL). This held true for albumin levels 2.3 to 2.6 g/dL for early [AdjOR 2.5, 95% CI = 1.2-5.5, p < 0.02] and late AKI [AdjOR 6.4, 95% CI = 1.9-21.6, p < 0.01]. Albumin quartiles of (2.7 to 3.0 g/dL) were associated with increased odds of late AKI. Albumin levels of 2.6 g/dL and 2.4 g/dL best predicted early (AUC = 0.59) and late AKI (AUC = 0.64), respectively. Analysis of albumin association with AKI by GA is described.
CONCLUSIONS: Low albumin levels are independently associated with early and late neonatal AKI. Albumin could be a potential modifiable risk factor for neonatal AKI.
© 2021. The Author(s), under exclusive licence to International Pediatric Nephrology Association.

Entities:  

Keywords:  Hypoalbuminemia; Infants; Kidney failure; Risk factors

Mesh:

Substances:

Year:  2021        PMID: 34657971     DOI: 10.1007/s00467-021-05295-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.651


  52 in total

1.  Potential risk factors for the development of acute renal failure in preterm newborn infants: a case-control study.

Authors:  L Cataldi; R Leone; U Moretti; B De Mitri; V Fanos; L Ruggeri; G Sabatino; F Torcasio; V Zanardo; G Attardo; F Riccobene; C Martano; D Benini; L Cuzzolin
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-11       Impact factor: 5.747

2.  Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions.

Authors:  Laura Cuzzolin; Vassilios Fanos; Bernadette Pinna; Maria di Marzio; Monica Perin; Paola Tramontozzi; Paola Tonetto; Luigi Cataldi
Journal:  Pediatr Nephrol       Date:  2006-05-25       Impact factor: 3.714

3.  Acute kidney injury in asphyxiated newborns treated with therapeutic hypothermia.

Authors:  David T Selewski; Brian K Jordan; David J Askenazi; Ronald E Dechert; Subrata Sarkar
Journal:  J Pediatr       Date:  2012-11-10       Impact factor: 4.406

4.  Acute kidney injury reduces survival in very low birth weight infants.

Authors:  Rajesh Koralkar; Namasivayam Ambalavanan; Emily B Levitan; Gerald McGwin; Stuart Goldstein; David Askenazi
Journal:  Pediatr Res       Date:  2011-04       Impact factor: 3.756

5.  Fluid overload and mortality are associated with acute kidney injury in sick near-term/term neonate.

Authors:  David J Askenazi; Rajesh Koralkar; Hayden E Hundley; Angela Montesanti; Neha Patil; Namasivayam Ambalavanan
Journal:  Pediatr Nephrol       Date:  2012-12-09       Impact factor: 3.714

6.  Acute kidney injury in a single neonatal intensive care unit in Turkey.

Authors:  Fatih Bolat; Serdar Comert; Guher Bolat; Oznur Kucuk; Emrah Can; Ali Bulbul; Hasan Sinan Uslu; Asiye Nuhoglu
Journal:  World J Pediatr       Date:  2013-11-14       Impact factor: 2.764

7.  Late onset neonatal acute kidney injury: results from the AWAKEN Study.

Authors:  Jennifer R Charlton; Louis Boohaker; David Askenazi; Patrick D Brophy; Mamta Fuloria; Jason Gien; Russell Griffin; Sangeeta Hingorani; Susan Ingraham; Ayesa Mian; Robin K Ohls; Shantanu Rastogi; Christopher J Rhee; Mary Revenis; Subrata Sarkar; Michelle Starr; Alison L Kent
Journal:  Pediatr Res       Date:  2018-12-13       Impact factor: 3.756

8.  The impact of fluid balance on outcomes in critically ill near-term/term neonates: a report from the AWAKEN study group.

Authors:  David T Selewski; Ayse Akcan-Arikan; Elizabeth M Bonachea; Katja M Gist; Stuart L Goldstein; Mina Hanna; Catherine Joseph; John D Mahan; Arwa Nada; Amy T Nathan; Kimberly Reidy; Amy Staples; Pia Wintermark; Louis J Boohaker; Russell Griffin; David J Askenazi; Ronnie Guillet
Journal:  Pediatr Res       Date:  2018-09-20       Impact factor: 3.756

9.  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates: Design of a Retrospective Cohort Study.

Authors:  Jennifer G Jetton; Ronnie Guillet; David J Askenazi; Lynn Dill; Judd Jacobs; Alison L Kent; David T Selewski; Carolyn L Abitbol; Fredrick J Kaskel; Maroun J Mhanna; Namasivayam Ambalavanan; Jennifer R Charlton
Journal:  Front Pediatr       Date:  2016-07-19       Impact factor: 3.418

10.  Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study.

Authors:  Jennifer G Jetton; Louis J Boohaker; Sidharth K Sethi; Sanjay Wazir; Smriti Rohatgi; Danielle E Soranno; Aftab S Chishti; Robert Woroniecki; Cherry Mammen; Jonathan R Swanson; Shanty Sridhar; Craig S Wong; Juan C Kupferman; Russell L Griffin; David J Askenazi
Journal:  Lancet Child Adolesc Health       Date:  2017-11
View more
  1 in total

Review 1.  Expectations in children with glomerular diseases from SGLT2 inhibitors.

Authors:  Luigi Cirillo; Fiammetta Ravaglia; Carmela Errichiello; Hans-Joachim Anders; Paola Romagnani; Francesca Becherucci
Journal:  Pediatr Nephrol       Date:  2022-03-14       Impact factor: 3.651

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.